« Return to News | Technology Solutions

CoE launches eTACT to authenticate drugs with smartphones

Monday, February 13, 2012 03:11 PM

The Council of Europe (CoE) and its European Directorate for the Quality of Medicines & HealthCare (EDQM) have launched eTACT, an IT-based traceability service that will allow patients to check the authenticity of their medicines using smartphones or the internet.

Part of the CoE’s global strategy to counter fake drugs, eTACT is a publicly governed service which covers all medicines in the legal supply chain and will trace drugs’ origins through existing national systems. The technology will be open to the 36 member states of the European Pharmacopoeia Commission and beyond.

EDQM organized a workshop in late January for stakeholders, regulatory authorities and patient organizations to use and discuss the technology. The International Alliance of Patients' Organizations specifically welcomed the EDQM’s initiative to open the service to patients and underlined the importance of value to patients versus costs.

Consultations, technical workshops and a series of webinars are to be organized in the coming months to help users understand the project and to gather ideas to create an optimum traceability environment for medicines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.